1699720-85-8
1699720-85-8
Chemical Structure
(S)-ML753286
- CAS No.: 1699720-85-8
- Formula:C20H25N3O3
- Molecular Weight:355.43
IUPAC Name: (3S,6S,12aS)-6-isobutyl-9-methoxy-3-methyl-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
InChIKey: XDVXQQDQFWVCAU-GOPGUHFVSA-N
SMILES: COC1=CC=C2C(NC3=C2C[C@]4([H])N(C([C@H](C)NC4=O)=O)[C@H]3CC(C)C)=C1
Biological Activity: (S)-ML753286 is a breast cancer resistance protein (BCRP) inhibitor with an IC50 of 0.6 μM on BCRP efflux transporter.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(S)-ML753286 | 99.39% | (S)-ML753286 is a breast cancer resistance protein (BCRP) inhibitor with an IC50 of 0.6 μM on BCRP efflux transporter. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(S)-ML753286 (Standard) | ≥98% | (S)-ML753286 (Standard) is the analytical standard of (S)-ML753286 (HY-100390). This product is intended for research and analytical applications. (S)-ML753286 is a breast cancer resistance protein (BCRP) inhibitor with an IC50 of 0.6 μM on BCRP efflux transporter. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ko 143 (Standard) | ≥98% | Ko 143 (Standard) is the analytical standard of Ko 143 (HY-10010). This product is intended for research and analytical applications. Ko 143 is a potent and selective ATP-binding cassette subfamily G member 2 (ABCG2/BCRP) inhibitor. Ko 143 displays >200-fold selectivity over P-gp and MRP-1 transporters. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ML753286 | ML753286 is an orally active and selective BCRP (Breast cancer resistance protein) inhibitor with an IC50 of 0.6 μM. ML753286 has high permeability and low to medium clearance in rodent and human liver S9 fractions, and is stable in plasma cross species. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ABCG2-IN-1 | ABCG2-IN-1 (compound K2), a Ko143 analog, is an orally active ABCG2 inhibitor with an IC50 of 0.13 μM. ABCG2-IN-1 has favorable oral pharmacokinetic profiles in mice. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ABCG2-IN-2 | ABCG2-IN-2 is a potent ABCG2 inhibitor with favorable oral pharmacokinetic profiles in mice. ABCG2-IN-2 can be used for the research of tumor multidrug resistance (MDR) and erythropoietic protoporphyria (EPP). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MZ82 | MZ82, Ko 143 (HY-10010) derivative, is a ATP-binding cassette subfamily G member 2 (ABCG2/BCRP) inhibitor with the IC50 of ~23 nM. MZ82 not only shows greatly improved metabolic stability over Ko 143 (HY-10010) in liver microsomes but also in mice, and is able to penetrate into the brain. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ABCG2-IN-4 | ABCG2-IN-4 (Compound K31) is an orally active inhibitor for ABCG2, which reduces the release of Protoporphyrin IX (PPIX) (HY-B1247) from erythrocytes into plasma, and prevents the reduces phototoxicity. ABCG2-IN-4 exhibits anti-inflammatory and antioxidant activity in mouse models. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
12R,13S-Dihydroxyfumitremorgin C | 12R,13S-Dihydroxyfumitremorgin C (compound 1) is a LXRα agonist. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fumitremorgin C | 99.92% | Fumitremorgin C is a potent and selective ABCG2/BRCP inhibitor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tryprostatin A | Tryprostatin A is an inhibitor of the mammalian cell cycle. Tryprostatins A can be isolated from the secondary metabolites of a marine fungal strain BM939. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Demethoxyfumitremorgin C | Demethoxyfumitremorgin C is a secondary metabolite of the marine fungus, Aspergillus fumigatus. Demethoxyfumitremorgin C induces prostate cancer cell apoptosis. Demethoxyfumitremorgin C activates caspase-3, -8, and -9, leading to PARP/ cleavage. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
